DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Pimavanserin

Pimavanserin

  • Serotonin 2A Activation and a Novel Therapeutic Drug

    Serotonin 2A Activation and a Novel Therapeutic Drug

  • Atypical Antipsychotics TCO 02.2018

    Atypical Antipsychotics TCO 02.2018

  • Reviews Insights Into Pathophysiology from Medication-Induced Tremor

    Reviews Insights Into Pathophysiology from Medication-Induced Tremor

  • Low Continuation of Antipsychotic Therapy in Parkinson Disease – Intolerance, Ineffectiveness, Or Inertia? Thanh Phuong Pham Nguyen1,2,3,4*, Danielle S

    Low Continuation of Antipsychotic Therapy in Parkinson Disease – Intolerance, Ineffectiveness, Or Inertia? Thanh Phuong Pham Nguyen1,2,3,4*, Danielle S

  • Pimavanserin: a Potentially Safer Alternative to Clozapine for Refractory Hallucinations and Delusions

    Pimavanserin: a Potentially Safer Alternative to Clozapine for Refractory Hallucinations and Delusions

  • Antipsychotics

    Antipsychotics

  • 122 Use of Pimavanserin in Patients with Parkinson's Disease Psychosis

    122 Use of Pimavanserin in Patients with Parkinson's Disease Psychosis

  • Pimavanserin (NUPLAZID)

    Pimavanserin (NUPLAZID)

  • BLACK-BOX WARNINGS: How They Can Improve Your Clinical Practice a Better Understanding of These Warnings Leads to Safer, More Effective Prescribing

    BLACK-BOX WARNINGS: How They Can Improve Your Clinical Practice a Better Understanding of These Warnings Leads to Safer, More Effective Prescribing

  • Louisiana Fee-For-Service Medicaid Antipsychotics

    Louisiana Fee-For-Service Medicaid Antipsychotics

  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease

    Medications to Be Avoided Or Used with Caution in Parkinson's Disease

  • Medications for Behavioral Changes in LBD

    Medications for Behavioral Changes in LBD

  • Pimavanserin Practice Based Recommendations

    Pimavanserin Practice Based Recommendations

  • Antipsychotics Therapeutic Class Review (TCR)

    Antipsychotics Therapeutic Class Review (TCR)

  • Update on Treatments for Non-Motor Symptoms of Parkinson's Disease

    Update on Treatments for Non-Motor Symptoms of Parkinson's Disease

  • Nuplazid (Pimavanserin Tartrate) Tablet/ Atypical Antipsychotics

    Nuplazid (Pimavanserin Tartrate) Tablet/ Atypical Antipsychotics

  • Therapeutic Class Overview Atypical Antipsychotics

    Therapeutic Class Overview Atypical Antipsychotics

  • 207318Orig1s000

    207318Orig1s000

Top View
  • Nuplazid (Pimavanserin)
  • Pimavanserin)
  • Pimavanserin Tartrate: a 5-HT2A Inverse Agonist with Potential for Treating Various 1
  • Official Title: a Phase 3, Randomized, Double-Blind, Placebo-Controlled
  • Download Product Insert (PDF)
  • The Neurobiology of Psychedelic Drugs: Implications for the Treatment
  • Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A
  • A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled
  • Medications.Pdf
  • Medical Alert Card
  • View Board (#17–0011)
  • New Drug Evaluation Monograph Template
  • Atypical Antipsychotics
  • Antipsychotic Update
  • New Treatments for Schizophrenia
  • NUPLAZID (Pimavanserin) RATIONALE for INCLUSION IN
  • New Drug Evaluation Monograph Template
  • Pimavanserin (Nuplazid®) EOCCO POLICY


© 2024 Docslib.org    Feedback